search icon
  • Print
  • ShareThis
  • Text Size
  • IDSA Statement on the Senate Appropriations action on the State and Foreign Operations and Labor, Health and Human Services FY 2018 funding bills


    IDSA commends Congressional appropriators’ support for global and domestic public health and research

    The members of the Infectious Diseases Society of America (IDSA) applaud Senate appropriators’ support for programs and initiatives addressing central and urgent public health and research priorities in the spending bills for fiscal year 2018 that they approved Thursday. With $2 billion in new funding allotted to the National Institutes of Health (NIH) that includes a $50 million increase for initiatives to combat antimicrobial resistance and the continued support for the global research Fogarty International Center, as well as a boost for U.S. led efforts against tuberculosis globally, and the bill’s return of funding for immunization programs to 2017 levels, the decisions reflect an understanding of some of the most serious challenges confronting global and domestic health security.  

    The Senators, importantly, have delivered a decisive rejection of White House proposals that threatened decades of progress in controlling infectious diseases, and critical efforts to protect the health of Americans at home and abroad.

    Meeting the public health needs ahead, through responsive programs and research remains essential, and we urge House appropriators to recognize priorities reflected in the Senate bill which:


    • Increased funding for the National Institute of Allergy and Infectious Diseases (NIAID) at NIH by $122 over the House proposal for 2018, to $5.127 billion;
    • Increased funding for the NIH’s Fogarty International Center by $1.027 million over the House proposal to $74.38 million;
    • Provides $7.18 billion for the Centers for Disease Control and Prevention (CDC), $15 million less than the 2017 level but $124 million more than the House proposal;
    • Maintains funding for CDC’s National Center for Zoonotic and Emerging Diseases responses with $584.922 million, $33 more than the House proposal;
    • Maintains funding for the CDC’s Antibiotic Resistance Solutions Initiative (ARSI) with $163 million;
    • Maintains funding for the Section 317 Immunization program at CDC with $606 million;
    • Maintains the CDC’s Global HIV funding with $128 million; and
    • Maintains funding for the Biomedical Advanced Research and Development Authority (BARDA), at $511.7 million.


    We are concerned that the Senate bill proposes a $2 million reduction in CDC’s global health programs and urge Congress to provide at least the current funding level of $435 million for these critical programs in the final spending bill.

    We appreciate the foresight Senate appropriators have shown by investing in a stronger and healthier future.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site